Drug Discovery

29 Oct 2019
- Drug Discovery
- Research & Development
Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development

By PBR Staff Writer

Gilead Sciences and Glympse Bio announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical programme.
23 Oct 2019
Drug Discovery
Research & Development
Takeda acquires TAK-101 license from COUR in $420m deal

By PBR Staff Writer

Takeda Pharmaceutical has signed a deal worth up to $420m with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise the latter’s CNP-101 (TAK-101).
23 Oct 2019
Drug Discovery
Research & Development
Zealand Pharma expands peptide platform with acquisition of Encycle Therapeutics

By PBR Staff Writer

Zealand Pharma, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the acquisition of Encycle Therapeutics, a private Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides exhibiting enhanced drug-like properties.
21 Oct 2019
Drug Discovery
Research & Development
Verseau launches with $50m to develop first-in-class macrophage-targeted immunotherapies

By PBR Staff Writer

Verseau Therapeutics, Inc. (“Verseau”) launched with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.
17 Oct 2019
Drug Discovery
Research & Development
Alexion to buy clinical-stage biopharmaceutical firm Achillion for $930m

By PBR Staff Writer

Alexion Pharmaceuticals has agreed to acquire clinical-stage biopharmaceutical company Achillion Pharmaceuticals in a deal valued at around $930m.
16 Oct 2019
Drug Discovery
Research & Development
CRISPR, KSQ Therapeutics join forces to advance cell therapies in oncology

By PBR Staff Writer

CRISPR Therapeutics and KSQ Therapeutics have signed license agreement to advance their respective cell therapy programmes in oncology.
11 Oct 2019
Drug Discovery
Research & Development
Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

By PBR Staff Writer

Belgium-based biopharmaceutical firm UCB has agreed to acquire US-based clinical-stage biopharmaceutical company Ra Pharmaceuticals in a deal valued at around $2.1bn.
11 Oct 2019
Drug Discovery
Research & Development
Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases

By PBR Staff Writer

Alexion Pharmaceuticals and Stealth BioTherapeutics have announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases.
10 Oct 2019
Drug Discovery
Research & Development
Viela Bio, Mitsubishi Tanabe sign licensing deal for inebilizumab

By PBR Staff Writer

Viela Bio has entered into a licensing deal with Mitsubishi Tanabe Pharma to develop and commercialize inebilizumab in nine Asian countries for the treatment of autoimmune and inflammatory diseases.
10 Oct 2019
Drug Discovery
Research & Development
NSF International purchases majority stake in Amarex CRO

By PBR Staff Writer

Global public health organisation NSF International has purchased a majority stake in US-based clinical stage contract research organisation (CRO) called Amarex Clinical Research.

Drug Discovery

Research & Development

Sanofi receives FDA approval for Tzield in paediatric diabetes

MSD teams up with Google Cloud on agentic AI transformation

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Drug Discovery

Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development

Takeda acquires TAK-101 license from COUR in $420m deal

Zealand Pharma expands peptide platform with acquisition of Encycle Therapeutics

Verseau launches with $50m to develop first-in-class macrophage-targeted immunotherapies

Alexion to buy clinical-stage biopharmaceutical firm Achillion for $930m

CRISPR, KSQ Therapeutics join forces to advance cell therapies in oncology

Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases

Viela Bio, Mitsubishi Tanabe sign licensing deal for inebilizumab

NSF International purchases majority stake in Amarex CRO

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found